Drugs / BC1 cell line
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06471673 | May 2024 → Apr 2025 overdue | breast cancer | BriaCell Therapeutics Corporation | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC1 cell line | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06471673 ↗ |
| Modality | Cell therapy | “allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity” NCT06471673 ↗ |